ClinicalTrials.gg
RecruitingNCT06655246Updated Oct 27, 2026

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

A Phase 1 interventional study of ziftomenib and imatinib mesylate in Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer and Gastrointestinal Stromal Neoplasm, sponsored by Kura Oncology, Inc.. Recruiting at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Kura Oncology, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 27, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
135
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Gastrointestinal Stromal Tumors with a site in United States — 19 open to participants now, 29 under way, 5 of them phase 3. Gastrointestinal Stromal Tumors · United States.

Planned enrollment
28th of 116
135 · median 55
Started
2025
with 4 others
Phase 1
32 of 139
3 open now
Primary completion
2029-06
later than 21 of 28 live
Registered
128th of 139
by date

Among the 139 studies in Gastrointestinal Stromal Tumors with a site in United States, this one is the 28th largest by planned enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2025, is one of 32 in phase 1, reaches primary completion later than 21 of the 28 other live ones, and was the 128th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

19 of the 139 studies in Gastrointestinal Stromal Tumors with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Gastrointestinal Stromal Tumors with a site in United States, or all of them as a file.
02

Study summary

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib as current or prior therapy, or are treatment naive.

03

Conditions studied

  • Gastrointestinal Stromal Tumor (GIST)
  • Gastrointestinal Stromal Cancer
  • Gastrointestinal Stromal Neoplasm
  • Gastrointestinal Stromal Tumor, Malignant
  • Gastrointestinal Stromal Cell Tumors

Keywords

  • Gastrointestinal Stromal Tumor
  • Gastrointestinal Stromal Cancer
  • Gastrointestinal Stromal Neoplasm
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Documented diagnosis of advanced/ KIT-mutant GIST
  • Documented disease progression on imatinib as current or prior therapy or is treatment naïve, as follows:

    • DES: Participant is progressing or progressed on imatinib in any .
    • EXP Cohort A: Participant is progressing or progressed on imatinib and has not received additional intervening therapy before study participation.
    • EXP Cohort B: Participant has progressed on imatinib and sunitinib only and has not received additional intervening therapy before study participation.
    • EXP Cohort C: Participant has newly diagnosed advanced/metastatic GIST and is treatment naïve in the advanced/metastatic setting.
  • (ECOG) performance status of ≤2 at screening.
  • At least 1 per v1.1 modified for GIST.
  • Negative pregnancy test for participants of .
  • Adequate organ function per protocol requirements.
  • Resolution of all toxicities from prior therapy to \<Grade 1 (or participant baseline) within 1 week before the first dose of study intervention.
  • Participant, or legally authorized representative, must be able to understand and provide written before the first screening procedure.

Key Exclusion Criteria:

  • Diagnosis of GIST without a KIT mutation or with a T670X KIT mutation.
  • History of prior or current cancer that has potential to interfere with obtaining study results.
  • Received a prohibited medication, including therapy, less than 14 days or within 5 drug half-lives before the first dose of study intervention.
  • Active central nervous system metastases.
  • Uncontrolled intercurrent illness, including, but not limited to protocol defined cardiac disease.
  • Mean interval (QTcF) greater than 470ms.
  • (LVEF) \<50%.
  • Major surgery within 2 weeks before the first dose of study intervention.
  • Is pregnant or breastfeeding.
  • Gastrointestinal abnormalities that may impact taking study intervention by mouth.
  • Actively bleeding, excluding hemorrhoidal or gum bleeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Intervention: ziftomenib plus imatinib. Participants with advanced/metastatic GIST who are progressing/progressed on imatinib

    Drug: ziftomenib · Drug: imatinib mesylate

  • Experimental
    Dose Expansion Cohort A

    Intervention: ziftomenib plus imatinib. Participants with advanced/metastatic GIST who are progressing/progressed on imatinib

    Drug: ziftomenib · Drug: imatinib mesylate

  • Experimental
    Dose Expansion Cohort B

    Intervention: ziftomenib plus imatinib. Participants with advanced/metastatic GIST who progressed on imatinib and sunitinib only

    Drug: ziftomenib · Drug: imatinib mesylate

  • Experimental
    Dose Expansion Cohort C

    Intervention: ziftomenib plus imatinib. Participants with newly diagnosed advanced/metastatic GIST who are treatment-naive in the advanced/metastatic setting

    Drug: ziftomenib · Drug: imatinib mesylate

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT) (Dose Expansion)

    Rate of DLTs per dose level

    Time frame: Cycle 1 (first 28 day cycle)

  2. Descriptive statistics of Adverse Events (AEs)

    Per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Time frame: First dose of ziftomenib up to and including 28 days after last dose of ziftomenib, or if the participant is lost to follow-up, whichever comes first

  3. Clinical Benefit Rate (CBR) (Dose Escalation and Dose Expansion Cohorts A and B only)

    CBR is the rate of participants achieving complete response (CR), partial response (PR), or stable disease (SD), assessed per Response Criteria in Solid Tumors (RECIST) v1.1 modified for GIST

    Time frame: Up to 2 years following start of treatment with ziftomenib

  4. Overall Response Rate (ORR) (Dose Expansion Cohort C)

    ORR is CR + PR assessed per RECIST v1.1 modified for GIST

    Time frame: Up to 2 years following start of treatment with ziftomenib

Secondary outcomes

  1. Overall Response Rate (ORR) (Dose Expansion Cohorts A and B)

    ORR is CR + PR assessed per RECIST v1.1 modified for GIST

    Time frame: Up to 2 years following start of treatment with ziftomenib

  2. Duration of Response (DoR)

    Defined as the time from the first response (CR or PR assessed per RECIST v1.1 modified for GIST) to disease progression or death from any cause

    Time frame: Up to 2 years following start of treatment with ziftomenib

  3. Progression-Free Survival (PFS)

    Assessed per RECIST v1.1 modified for GIST

    Time frame: Up to 2 years following start of treatment with ziftomenib

  4. Overall Survival (OS)

    Defined as the time from first dose of ziftomenib or imatinib (whichever is dosed first) until death from any cause

    Time frame: Up to 2 years following start of treatment with ziftomenib

  5. Maximum plasma concentration (Cmax)

    Cmax of ziftomenib

    Time frame: Day 1 of each cycle; each cycle is 28 days

  6. Time to maximum plasma concentration (Tmax)

    Tmax of ziftomenib

    Time frame: Day 1 of each cycle; each cycle is 28 days

  7. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC 0-last)

    AUC 0-last of ziftomenib

    Time frame: Day 1 of each cycle; each cycle is 28 days

  8. Area under the concentration-time curve over a dosing interval (AUC tau)

    AUC 0-t of ziftomenib

    Time frame: Day 1 of each cycle; each cycle is 28 days

  9. Maximum plasma concentration (Cmax)

    Cmax of imatinib

    Time frame: Day 1 of each cycle; each cycle is 28 days

  10. Time to maximum plasma concentration (Tmax)

    Tmax of imatinib

    Time frame: Day 1 of each cycle; each cycle is 28 days

  11. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC 0-last)

    AUC 0-last of imatinib

    Time frame: Day 1 of each cycle; each cycle is 28 days

  12. Area under the concentration-time curve over a dosing interval (AUC tau)

    AUC 0-t of imatinib

    Time frame: Day 1 of each cycle; each cycle is 28 days

07

Study locations

32 of 32 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2029, 51 months after the start.

Of 21 phase 1 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 77. This study's planned 51 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2027 → Jun 2029 and completion Dec 2028 → Jun 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 23, 2024
StartActual
Mar 27, 2025
Primary completionEst.
Jun 2029was Dec 2027
CompletionEst.
Jun 2030was Dec 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2027→Jun 2029
Oct 27, 2026
Study completion
Dec 2028→Jun 2030
Oct 27, 2026
Enrollment
157→135
Oct 27, 2026
Eligibility
1 criterion edited, 4 added
What changed in the criteria
  • EditedDocumented disease progression on imatinib as current or prior therapy. or is treatment naïve, as follows:
  • AddedDES: Participant is progressing or progressed on imatinib in any prior line of therapy.
  • AddedEXP Cohort A: Participant is progressing or progressed on imatinib and has not received additional intervening therapy before study participation.
  • AddedEXP Cohort B: Participant has progressed on imatinib and sunitinib only and has not received additional intervening therapy before study participation.
  • AddedEXP Cohort C: Participant has newly diagnosed advanced/metastatic GIST and is treatment naïve in the advanced/metastatic setting.
Oct 27, 2026
Interventions
Arm changed Dose Expansion→Dose Expansion Cohort A. Arms added: Dose Expansion Cohort B·Dose Expansion Cohort C; arms removed: Recommended Phase 2 Dose Determination
Oct 27, 2026
Primary outcomes
2 edited, 1 added
What changed in the outcomes
  • EditedDose Escalation: Dose Limiting Toxicity (DLT) (Dose Expansion)Time frame: Cycle 1 (first 28 day cycle)
  • ChangedBefore Dose Expansion: Clinical benefit rate (CBR)Now Clinical Benefit Rate (CBR) (Dose Escalation and Dose Expansion Cohorts A and B only)Time frame: Up to 2 years following start of treatment with ziftomenib
  • AddedOverall Response Rate (ORR) (Dose Expansion Cohort C)Time frame: Up to 2 years following start of treatment with ziftomenib
Oct 27, 2026
Secondary outcomes
2 edited, 1 removed, 2 description edited
What changed in the outcomes
  • EditedOverall Response Rate (ORR) (Dose Expansion Cohorts A and B)Time frame: Up to 2 years following start of treatment with ziftomenib
  • EditedProgression -Free Survival (PFS)Time frame: Up to 2 years following start of treatment with ziftomenib
  • RemovedRecommended Phase 2 Dose Determination and Dose Expansion: CBRTime frame: Up to 2 years following start of treatment with ziftomenib
  • DescriptionArea under the concentration-time curve over a dosing interval (AUC tau): how it is measured was reworded
  • DescriptionArea under the concentration-time curve over a dosing interval (AUC tau)#2: how it is measured was reworded
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Dec 2027→Jun 2029
    Study completion Dec 2028→Jun 2030
    Enrollment 157→135
    Eligibility 1 criterion edited, 4 added
    What changed in the criteria
    • EditedDocumented disease progression on imatinib as current or prior therapy. or is treatment naïve, as follows:
    • AddedDES: Participant is progressing or progressed on imatinib in any prior line of therapy.
    • AddedEXP Cohort A: Participant is progressing or progressed on imatinib and has not received additional intervening therapy before study participation.
    • AddedEXP Cohort B: Participant has progressed on imatinib and sunitinib only and has not received additional intervening therapy before study participation.
    • AddedEXP Cohort C: Participant has newly diagnosed advanced/metastatic GIST and is treatment naïve in the advanced/metastatic setting.
    Primary outcomes 2 edited, 1 added
    What changed in the outcomes
    • EditedDose Escalation: Dose Limiting Toxicity (DLT) (Dose Expansion)Time frame: Cycle 1 (first 28 day cycle)
    • ChangedBefore Dose Expansion: Clinical benefit rate (CBR)Now Clinical Benefit Rate (CBR) (Dose Escalation and Dose Expansion Cohorts A and B only)Time frame: Up to 2 years following start of treatment with ziftomenib
    • AddedOverall Response Rate (ORR) (Dose Expansion Cohort C)Time frame: Up to 2 years following start of treatment with ziftomenib
    Secondary outcomes 2 edited, 1 removed, 2 description edited
    What changed in the outcomes
    • EditedOverall Response Rate (ORR) (Dose Expansion Cohorts A and B)Time frame: Up to 2 years following start of treatment with ziftomenib
    • EditedProgression -Free Survival (PFS)Time frame: Up to 2 years following start of treatment with ziftomenib
    • RemovedRecommended Phase 2 Dose Determination and Dose Expansion: CBRTime frame: Up to 2 years following start of treatment with ziftomenib
    • DescriptionArea under the concentration-time curve over a dosing interval (AUC tau): how it is measured was reworded
    • DescriptionArea under the concentration-time curve over a dosing interval (AUC tau)#2: how it is measured was reworded
    Interventions Arm changed Dose Expansion→Dose Expansion Cohort A. Arms added: Dose Expansion Cohort B·Dose Expansion Cohort C; arms removed: Recommended Phase 2 Dose Determination
    + 3 other changes: verification date, registry dates and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06655246
Lead sponsor
Kura Oncology, Inc.
Responsible party
Sponsor
First posted
Oct 23, 2024
Start date
Mar 27, 2025
Primary completion
Jun 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

Kura Medical Information 844-KURAONC
Contact
medinfo@kuraoncology.com
844-587-2662

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziftomenib

Start the discussion